Yachen Zang1, Yun Dong2, Dongrong Yang1, Boxin Xue1, Feng Li3, Peng Gu1, Haifeng Zhao3, Shaoxiong Wang1, Songlin Zhou1, Rong Ying4, Zhou Wang5,6,7, Yuxi Shan8. 1. Department of Urology, The Second Affiliated Hospital of Soochow University, 1055 Sanxiang Road, Suzhou, 215004, China. 2. Department of Pathology, Wuxi Hospital of Traditional Chinese Medicine, Wuxi, China. 3. Department of Pathology, The Second Affiliated Hospital of Soochow University, Suzhou, China. 4. Department of Urology, Nanjing Medical University Affiliated Suzhou Hospital, Suzhou, China. 5. Department of Urology, University of Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. 6. Department of Molecular Pharmacology and Chemical Biology, University of Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. 7. Department of Pathology, University of Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. 8. Department of Urology, The Second Affiliated Hospital of Soochow University, 1055 Sanxiang Road, Suzhou, 215004, China. shanyx1002@yeah.net.
Abstract
PURPOSE: ELL-associated factor 2 (EAF2) is an androgen-regulated tumor suppressor in the prostate. The purpose of this study was to investigate the expression of EAF2 protein in human prostate cancer specimens along with BPH specimens as a control, and to evaluate potential association of EAF2 expression with clinical characteristics and overall survival of the prostate cancer patients. METHODS: The expression of EAF2 was evaluated in 44 prostate cancer and 23 BPH tissue specimens using immunohistochemistry. The relationships of EAF2 expression with clinical characteristics and overall survival rates were analyzed by Chi-square test and Kaplan-Meier method. RESULTS: The immunostaining intensity of EAF2 in BPH specimens was significantly higher than that in prostate cancer (p < 0.05). EAF2 expression decreased significantly in high-grade and advanced-stage human prostate tumors and inversely correlated with PSA level, Gleason scores, bone metastasis and tumor stage. Importantly, loss of EAF2 expression was associated with a significant decrease in patient survival. CONCLUSION: Expression of EAF2 is decreased in prostate carcinogenesis, and EAF2 loss is associated with high-risk patients and poor survival.
PURPOSE:ELL-associated factor 2 (EAF2) is an androgen-regulated tumor suppressor in the prostate. The purpose of this study was to investigate the expression of EAF2 protein in humanprostate cancer specimens along with BPH specimens as a control, and to evaluate potential association of EAF2 expression with clinical characteristics and overall survival of the prostate cancerpatients. METHODS: The expression of EAF2 was evaluated in 44 prostate cancer and 23 BPH tissue specimens using immunohistochemistry. The relationships of EAF2 expression with clinical characteristics and overall survival rates were analyzed by Chi-square test and Kaplan-Meier method. RESULTS: The immunostaining intensity of EAF2 in BPH specimens was significantly higher than that in prostate cancer (p < 0.05). EAF2 expression decreased significantly in high-grade and advanced-stage humanprostate tumors and inversely correlated with PSA level, Gleason scores, bone metastasis and tumor stage. Importantly, loss of EAF2 expression was associated with a significant decrease in patient survival. CONCLUSION: Expression of EAF2 is decreased in prostate carcinogenesis, and EAF2 loss is associated with high-risk patients and poor survival.
Entities:
Keywords:
ELL-associated factor 2 (EAF2); Overall survival; Prognosis; Prostate cancer
Authors: Y E Whang; X Wu; H Suzuki; R E Reiter; C Tran; R L Vessella; J W Said; W B Isaacs; C L Sawyers Journal: Proc Natl Acad Sci U S A Date: 1998-04-28 Impact factor: 11.205
Authors: Stephanie E Kong; Charles A S Banks; Ali Shilatifard; Joan Weliky Conaway; Ronald C Conaway Journal: Proc Natl Acad Sci U S A Date: 2005-07-08 Impact factor: 11.205
Authors: W Xiao; Q Zhang; G Habermacher; X Yang; A-Y Zhang; X Cai; J Hahn; J Liu; M Pins; L Doglio; R Dhir; J Gingrich; Z Wang Journal: Oncogene Date: 2007-09-17 Impact factor: 9.867
Authors: J Ai; L E Pascal; K J O'Malley; J A Dar; S Isharwal; Z Qiao; B Ren; L H Rigatti; R Dhir; W Xiao; J B Nelson; Z Wang Journal: Oncogene Date: 2013-05-27 Impact factor: 9.867
Authors: M Yoshimoto; I W Cunha; R A Coudry; F P Fonseca; C H Torres; F A Soares; J A Squire Journal: Br J Cancer Date: 2007-08-14 Impact factor: 7.640